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Abstract
Background: Asthma is characterised by increased numbers of Th2-like cells in the airways and IgE secretion.
Generation of Th2 cells requires interleukin (IL)-4 and IL-13 acting through their specific receptors and activating
the transcription factor, signal transducer and activator of transcription 6 (STAT6). STAT6 knockout mice fail to
produce IgE, airway hyperresponsiveness and bronchoalveolar lavage eosinophilia after allergen sensitisation,
suggesting a critical role for STAT6 in allergic responses.
Methods: We have investigated the expression of STAT6 in peripheral blood T-lymphocytes, alveolar macrophages
and bronchial biopsies from 17 normal subjects and 18 mild-moderate steroid-naïve stable asthmatic patients.
Results: STAT6 expression was variable and was detected in T-lymphocytes, macrophages and bronchial epithelial
cells from all subjects with no difference between normal and stable asthmatic subjects.
Conclusions: STAT6 expression in different cells suggests that it may be important in regulating the expression of
not only Th2-like cytokines in T cells of man, but may also regulate STAT-inducible genes in alveolar macrophages
and airway epithelial cells.
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Introduction
Asthma is characterised by chronic airway inflammation,
with infiltration of T-lymphocytes, mast cells, eosinophils
and monocytes/macrophages. This is associated with the
increased expression of several inflammatory proteins,
including cytokines, enzymes, receptors and adhesion
molecules [1]. The molecular pathways involved in the
induction of chronic cytokine expression and recruitment
to the airways and activation of inflammatory cells in
asthma are not well understood. However, there is increas-
ing recognition that these processes involve increased
transcription of inflammatory genes, and that this is regu-
lated by transcription factors [1]. Several transcription fac-
tors are involved in asthmatic inflammation including
nuclear factor-B (NF-B) [2,3] and activator protein-1
(AP-1) [4].
CD4+ T helper (Th) cells can be divided into four major
subsets termed Th1, Th2, Th17 and Th0 based on the pat-
tern of cytokines they produce. More recently, another two
subsets of effector CD4+ Th cells, named Th9 and Th22
cells, have been described, even if their pathophysiological
meaning is still unclear [5,6]. Th1 cells produce predomi-
nantly interferon gamma (IFNg) and predominantly pro-
mote cell-mediated immune responses, whereas Th2 cells,
which produce mainly IL-4, IL-5 and IL-13, provide help
for some B cell responses. IL-4 and IL-13 in particular are
the major inducers of B cell switching to IgE production,
and therefore play a crucial role in allergic reactions invol-
ving IgE and mast cells including bronchial asthma [7].
Th0 cells produce both Th1 and Th2 type cytokines and
are precursors to Th1 and Th2 cells [5,6]. Th17 cells
release IL-17A, IL-17F and have been implicated in neutro-
phils recruitment and more severe disease [8]. Of note, a
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substantial proportion of human Th17 cells produce IFNg
in addition to IL-17A, and these cells were named Th17/
Th1 [5].
Recent data suggest the involvement of several tran-
scription factors in the molecular mechanisms by which
Th1 and Th2 cells differentially express Th1 and Th2
cytokines genes. For example, differentiation of Th2 cells
requires activation of GATA-3 [9] and signal transducer
and activator of transcription 6 (STAT6) [10] in mice.
Binding of IL-4 and IL-13 with their receptors activates
at least two distinct signal transduction pathways, which
regulate transcription of specific STAT6-responsive
genes. One pathway is associated with the activation of
Janus kinase (JAK) 1, 2 and 3. JAK1-3 kinases can, in
turn, phosphorylate STAT6 at tyrosine 641, which subse-
quently forms biologically active homodimers that move
from the cytoplasm to the nucleus and regulate transcrip-
tion of specific STAT6-responsive genes [11]. Generation
of Th2-like cells and IgE secretion by IL-4 and IL-13 are
mediated by STAT6 in mice [12]. In fact, STAT6 knock-
out mice have no response to IL-4 and IL-13, do not
develop Th2 cells in response to IL-4, fail to produce IgE,
airway hyperresponsiveness and bronchoalveolar lavage
eosinophilia following allergen sensitisation [13]. This
demonstrates the critical role of the STAT6 pathway in
allergic responses in mice [14].
Previous data investigating the localisation of STAT6 in
the airways of man has produced divergent results. In two
studies STAT6 is present only within infiltrating cells of
the nose and bronchial mucosa [15,16], whilst in another
study STAT6 is expressed predominantly within the bron-
chial epithelium of mild asthmatic subjects [17].
In order to confirm the site of STAT6-responsive gene
expression and activation we have investigated the
expression of STAT6 and phosphorylated (activated)
STAT6 proteins in peripheral venous blood T cells,
alveolar macrophages and bronchial biopsies of normal
and asthmatic subjects using Western blotting and
immunolocalisation.
Materials and methods
Patients
Eighteen mild-moderate asthmatic patients who fulfil the
American Thoracic Society Criteria for asthma [18] and
17 age and sex-matched normal subjects were recruited at
the Airway Disease Section of the National Heart and
Lung Institute of London. The characteristics of normal
and asthmatic subjects are summarised in Table 1. All
asthmatic patients demonstrated a > 12% improvement in
forced expiratory volume in one second (FEV1) following
inhalation of 200 μg of salbutamol and airway hyperre-
sponsiveness to methacholine with a provocative concen-
tration of methacholine producing a 20% fall in FEV1
(PC20) of < 8 mg/ml. All asthmatic patients were atopic as
defined by two or more positive skin prick tests to com-
mon aeroallergens. All asthmatic patients had stable
asthma and had not been receiving inhaled or oral gluco-
corticoid therapy for at least 1 year, and were using only
inhaled -agonists drugs intermittently for relief of symp-
toms. Current smokers or ex-smokers of more than five
pack years and patients with FEV1 < 75% predicted were
excluded. All normal subjects had normal lung function,
negative skin prick tests to common allergens (except one
subject), no bronchial hyperresponsiveness to methacho-
line (PC20 > 32 mg/ml) and were non-smokers. The study
was approved by the Royal Brompton Hospital Ethics
Committee and all subjects gave their informed consent.
Peripheral venous T cells separation
Peripheral venous blood (100 ml) was collected (between
08:00 and 09:00 h) into sterile 60 ml syringes containing
5 ml of 100% ACD (dextroglucose and Na2H Citrate solu-
tion). Erythrocyte sedimentation was increased by mixing
the blood 1:1 with a solution containing 20 ml of Elohaes
(Baxter, Thetford, UK) and 5 ml of 10% ACD (100% ACD
diluted in saline). After sedimentation for 60 minutes at
room temperature the plasma fraction was layered on
Ficoll Paque (Amersham Pharmacia Biotech, Little Chal-
font, UK) and after density gradient centrifugation, mono-
nuclear cells (PBMCs) were isolated. Following isolation of
PBMCs, T cells were isolated by negative selection of pan
T cells by depletion of B cells, monocytes, NK cells, den-
dritic cells, early erythroid cells, platelets and basophils
using magnetic beads according to the manufacture
instructions (Miltenyi Biotec, Bisley, UK), as previously
described [19]. In some experiments CCR5+ cells were
further isolated from T-cells by immunomagnetic beads
and subsequently analyzed for STAT6 expression by
immunocytochemistry.
Fibreoptic bronchoscopy, collection and processing of
bronchial biopsies, brushings and bronchoalveolar lavage
Normal subjects and asthmatic patients attended the
bronchoscopy suite at 8.30 am after having fasted from
midnight and were pre-treated with atropine (0.6 mg IV)
and midazolam (5-10 mg IV). Oxygen (3 l/min) was
administered via nasal prongs throughout the procedure
and oxygen saturation was monitored with a digital oxi-
meter. Using local anaesthesia with lidocaine (4%) to the
upper airways and larynx, a fiberoptic bronchoscope
(Olympus BF10 Key-Med, Southend, UK) was passed
through the nasal passages into the trachea. Further lido-
caine (2%) was sprayed into the lower airways, and four
bronchial mucosal biopsy specimens were taken from
segmental and subsegmental airways of the right lower
and upper lobes using size 19 cupped forceps. Bronchial
biopsies for immunohistochemistry were immediately
placed in optimal cutting temperature (OCT) embedding
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media, then snap frozen in isopentane, pre-cooled with
liquid nitrogen, and stored at -70°C. Bronchial biopsies
for Western blot analysis were immediately placed on ice
and processed as described later. All biopsies were frozen
within 20 minutes of collection. Six-micron sections were
placed on poly-L-lysine coated microscope slides, air
dried for 30 minutes then wrapped in aluminium foil and
stored at -70°C prior to immunostaining.
Brushing of the airway was performed with a 2 mm
diameter channel cytology brush (Olympus BC-16 C)
inserted via the sampling channel of the bronchoscope
and rubbed against the epithelial surface. The brush was
retracted and retrieved cells dissociated by vortexing in
Ham’s F12 nutrient medium. This brushing procedure
was repeated 8-10 times. Bronchial epithelial cells
smears (10,000 cells/slide) were made using a centrifuge
(Shandon Cytospin 3, Southend, UK). The cells were
air-dried onto the slides and fixed for 10 min in cold 4%
phosphate-buffered paraformaldehyde solution.
Bronchoalveolar lavage (BAL) was performed from the
right middle lobe using warmed 0.9% NaCl with 4 succes-
sive aliquots of 60 mls. Bronchoalveolar lavage fluid was
filtered through sterile gauze and centrifuged at 500 g for
10 minutes. BAL cells were washed twice with sterile
Table 1 Characteristics of subjects
Normals AGE SEX SKIN-TEST FEV1 (% pred) FVC (%pred) PC20 (mg/ml)
1 38 M negative 110 105 > 32
2 32 M negative 102 108 > 32
3 20 M negative 98 102 > 32
4 23 M positive 87 91 > 32
5 20 M negative 83 85 > 32
6 22 F negative 112 108 > 32
7 20 M negative 89 110 > 32
8 33 F positive 92 97 > 32
9 24 M negative 98 106 > 32
10 38 M negative 93 97 > 32
11 22 F negative 85 92 > 32
12 33 M negative 106 104 > 32
13 40 M negative 96 95 N/A
14 36 M negative 105 101 N/A
15 24 F negative 98 100 N/A
16 39 F negative 102 103 N/A
17 23 M negative 106 107 N/A
Asthmatics AGE SEX SKIN-TEST FEV1 (% pred) FVC (%pred) PC20 (mg/ml)
1 26 F positive 82 100 N/A
2 24 M positive 80 84 N/A
3 40 M positive 82 96 1.2
4 27 F positive 108 101 4.25
5 33 M positive 78 97 0.78
6 32 M positive 88 95 N/A
7 23 F positive 70 83 0.11
8 37 M positive 106 100 N/A
9 33 M positive 96 102 1.14
10 29 M positive 96 105 N/A
11 28 M positive 85 98 0.46
12 27 F positive 77 96 0.36
13 25 F positive 84 100 2.5
14 30 M positive 81 90 N/A
15 31 M positive 82 92 0.25
16 22 M N/A 95 97 2.32
17 47 M N/A 100 102 3.48
18 23 M N/A 95 99 0.54
FEV1, forced expiratory volume in one second; FVC, forced vital capacity. PC20, provocative concentration of methacholine causing a 20% fall in FEV1. N/A = not
available
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HBSS. Cytospins were prepared and stained with May-
Grunwald stain for differential cell counts. Cells were >
85% viable as assessed by trypan blue exclusion. Macro-
phages were purified by adhesion as previously described
[19].
Western blot analysis
Whole cell proteins were extracted from T cells, alveolar
macrophages and bronchial biopsies as previously
described [19]. In brief, T cells, alveolar macrophages and
bronchial biopsies were resuspended with mechanical
disruption in 30-100 l of 1 × reporter lysis buffer (Pro-
mega, Southampton, UK) with a protease inhibitors cock-
tail (Roche Molecular Biochemicals, Lewes, UK) and
phosphatase inhibitors (sodium fluoride and activated
sodium orthovanadate), immediately frozen to -70°C and
subjected to 3 freeze-thaw steps. Particulate matter was
removed by centrifugation at 12000 × g for 10 min at
4°C. Protein concentration was measured in the superna-
tant by the Bradford method according to the manufac-
turer’s instructions (Bio-Rad Laboratories, Hemel
Hempstead, UK). 30 g/lane of whole-cell proteins were
subjected to 8% SDS-polyacrylamide gel electrophoresis,
and transferred to nitrocellulose filters (Hybond-ECL,
Amersham Pharmacia Biotech) by blotting. Filters were
blocked for 45 minutes at room temperature in tris-
buffered saline (TBS), 0.05% Tween 20, 5% non-fat dry
milk. The filters were then incubated with rabbit antihu-
man STAT6 antibody (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) and rabbit anti-phosphorylated human
(Tyr641) STAT6 antibody (New England Biolabs,
Hitchin, UK) for 1 h at room temperature in TBS, 0.05%
Tween 20, 5% non-fat dry milk at dilution of 1:1000. The
first antibody is specific for both phosphorylated and
non-phosphorylated STAT6, the second antibody detects
only pSTAT6 phosphorylated at Tyr641. Neither anti-
body cross-reacts with other STAT proteins. IL-4 stimu-
lated HeLa cell extracts (New England Biolabs) were used
as a positive control. Filters were washed three times in
TBS, 0.5% Tween 20 and after incubated for 45 minutes
at room temperature with anti-rabbit antibody conju-
gated to horseradish peroxidase (Dako, Ely, UK) in TBS,
0.05% Tween 20, 5% non-fat dry milk, at dilution of
1:4000. After further three washes in TBS, 0.05% Tween
20 visualisation of the immunocomplexes was performed
using the ECL as recommended by the manufacturer
(Amersham Pharmacia Biotech). As an internal control
we reprobed each filter with an anti-human actin anti-
body (Santa Cruz Biotechnology).
The 43 kDa (actin) or 100 kDa (STAT6 and pSTAT6)
bands were quantified using densitometry with Grab-It
and GelWorks software (UVP, Cambridge, UK) and
expressed as the ratio with the corresponding actin opti-
cal density value of the same lane.
Immunohistochemistry for STAT6 in the bronchial
biopsies
Sections were fixed with cold 4% phosphate-buffered par-
aformaldehyde solution. The biopsies were washed repeat-
edly with phosphate-buffered saline (PBS). The sections
were treated with 0.1% saponin in PBS. Endogenous per-
oxidase activity was blocked by incubating slides in 1%
hydrogen peroxide (H2O2) and 0.02% sodium azide in PBS
for 1 h, followed by washing in PBS. Non-specific labelling
was blocked by coating with blocking serum (0.1 M phos-
phate buffer containing 1% bovine serum albumin and
10% normal swine serum) for 1 h at room temperature.
After washing in PBS the sections were incubated over-
night at 4°C with a rabbit polyclonal anti-human STAT6
antibody (Santa Cruz Biotechnology) at dilutions of 1:100
of a 200 μg/ml solution.
For the negative control slides, we did not add the
respective primary antibody and in some slides normal
rabbit non-specific immunoglobulins (Vector Laboratories,
Orton Southgate, UK) were used at the same protein con-
centration as the primary antibody. After overnight incu-
bation and repeated washing steps with PBS, the sections
were subsequently incubated with anti-rabbit biotinylated
antibody (1:200 dilution; Dako) for 45 minutes at room
temperature. After further washing the sections were sub-
sequently incubated with avidin-horseradish peroxidase
(1:200 dilution; Dako) for 45 minutes at room tempera-
ture. Slides were then incubated with chromogen-fast dia-
minobenzidine for 5 minutes, after which they were
counterstained in hematoxylin and mounted on mounting
medium (DPX).
Quantification
Counts of positive cells were made on all biopsy sections,
and were divided according to whether the positive cells
were in the airway epithelium or beneath the epithelium
to a depth of 175μm. Counts were made only in areas of
intact epithelium. For STAT6 proteins, the number of
positive cells was expressed as a percentage of nucleated
cells in the epithelium and in the subepithelium in at least
4 fields at x400 magnification. For the inflammatory cells,
the number of positive cells was expressed as the number
per field. For the epithelium, one field was defined as a
length of 175μm, and for the subepithelium one field was
defined as an area of 175μm2. At least four fields were
counted for each subject for the epithelium and subepithe-
lium. An experienced observer made all counts unaware of
the clinical status or the origin of the sections.
Immunocytochemical staining for STAT6 in T cells
Cytospins of T cells were fixed with cold 4% phosphate-
buffered paraformaldehyde solution. Cytospins were
washed repeatedly with PBS. Endogenous peroxidase
activity was blocked by incubating slides in 3% hydrogen
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peroxide (H2O2) in methanol for 1 h, followed by wash-
ing in PBS. Non-specific labelling was blocked by coating
with blocking serum (5% normal goat serum) for 20 min-
utes at room temperature. The cell membranes were per-
meabilised adding to the blocking serum 0.5% Triton
X-100. After washing in PBS the cells were incubated for
1 h with rabbit polyclonal anti-human STAT6 antibody
(Santa Cruz Biotechnology) at dilutions of 1:50 of a
200 μg/ml solution.
For the negative control slides, we did not add the
respective primary antibody and in some slides normal
rabbit non-specific immunoglobulins (http://www.scbt.
com) were used at the same protein concentration as the
primary antibody. After incubation and repeated washing
steps with PBS, the cells were subsequently incubated with
anti-rabbit biotinylated antibody (Vector Laboratories) for
30 minutes at room temperature. After further washing
the sections were subsequently incubated with ABC
reagent (Vector Laboratories) for 30 minutes at room tem-
perature. Slides were then incubated with chromogen-fast
diaminobenzidine for 5 minutes after which they were
counterstained in haematoxylin and mounted on perma-
nent mounting medium (DPX).
Statistical analysis
Data are presented as mean ± SD. Differences between
normal and asthmatic subjects were assessed with the
Mann-Whitney U-test, and a value of p < 0.05 was taken
as significant.
Results
T-Lymphocytes
Western blot analysis of isolated T cells showed no signifi-
cant difference in the expression of STAT6 in steroid-
naive asthmatic patients compared to normal subjects
(0.73 ± 0.18 vs 0.72 ± 0.22; not significant) (Figure 1).
There was no expression of pSTAT6 in either normal sub-
jects or asthmatic patients (Figure 1C) although a p-
STAT6 band was detected in the positive control lane.
Immunostaining indicated that STAT6 expression was
mainly but not exclusively confined to the cytoplasm.
STAT6 was found in the nucleus of some T cells isolated
from both normal and mild-moderate steroid-naïve asth-
matic subjects (Figure 2A). Using the chemokine receptor
CCR5 as a marker for Th1 cells [20] we examined the
expression of STAT6 in CCR5+ and CCR5- cells isolated
from freshly isolated human T-cells. STAT6 was highly
expressed and localised predominantly within the nucleus
of CCR5-(Th2-like) cells compared with minimal cytoplas-
mic expression within CCR5+ (Th1-like) cells (Figure 2B
& 2C). There was no difference in the number of CCR5+
and CCR5- cells between normal and asthmatic subjects.
The pSTAT6 antibody is not able to detect protein by
immunocytochemistry or immunohistochemistry (data
not shown).
Alveolar macrophages
Using Western blot analysis in alveolar macrophages we
observed the presence of STAT6 protein, both in nor-
mal subjects and in asthmatic patients. There was no
difference in the expression of STAT6 protein between
the two groups of subjects (0.65 ± 0.16 vs 0.65 ± 0.16;
not significant) (Figure 3). There was no discernable
expression of pSTAT6 in either normal subjects or asth-
matic patients using Western blotting (Figure 3C)
although a p-STAT6 band was detected in the positive
control lane.
Representative Western blot analyses of experiments
from 3 individual subjects in each group are shown (A).
Actin expression is used to control for protein loading.
Graphical representation of the data in (A) is shown in
B. (C) Failure to detect phospho-STAT6 (pSTAT6) pro-
tein expression in alveolar macrophages isolated from
As and N subjects. pSTAT6 expression in control IL-4
stimulated HeLa cells confirms the ability of the anti-
body to detect pSTAT6. Each circle represents one sub-
ject. Horizontal bars represent median values
Figure 1 STAT6 protein expression in peripheral blood T-
lymphocytes isolated from asthmatic (As) and normal (N)
subjects. Representative Western blot analyses of experiments from
3 individual subjects in each group are shown (A). Actin expression
is used to control for protein loading. Graphical representation of
the data in (A) is shown in (B). (C) Failure to detect phospho-STAT6
(pSTAT6) protein expression in peripheral blood T-lymphocytes
isolated from As and N subjects. pSTAT6 expression in control Th2
cells confirms the ability of the antibody to detect pSTAT6. Each
circle represents one subject. Horizontal bars represent median
values.
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Bronchial biopsies
Immunohistochemical staining (Figure 4) shows that most
of the cells staining for the STAT6 protein are bronchial
epithelial cells in both normal subjects and asthmatic
patients. However, there were some STAT6 positive cells
in the lamina propria both in normal and in asthmatic
patients (Figure 4). Western blot analysis indicated that
there was variable expression of STAT6 but no significant
difference in the expression of STAT6 protein (normalised
for the actin ratio) in bronchial biopsies of normal subjects
compared to asthmatic subjects (0.82 ± 0.5 vs 0.89 ± 0.28;
not significant) (Figure 4). Using Western blot analysis we
were unable to detect pSTAT6 expression in bronchial
biopsies of normal subjects compared with asthmatic
patients (Figure 5C) although a p-STAT6 band was
detected in the positive control lane.
Discussion
T cells isolated from peripheral venous blood of normal
subjects and steroid-naïve stable asthmatic patients
expressed STAT6 protein. However there was no
increased expression in T cells from asthmatic patients
compared to normal subject or in its activation. This is in
accordance with a previous study that found similar levels
of STAT6 in PBMCs from normal subjects and patients
with extrinsic asthma [21]. This suggests that either there
is no increase in activated Th2 cells in the blood in the
predominantly mild, stable, asthmatic patients studied
here or that STAT6 activation is not important for this
process. This further suggests that Th2-like gene regula-
tion in man may be controlled, at least in part by the
expression of proteins distinct from those predicted by
studies in human cell lines or in the mouse. For example,
many animal and human in vitro studies suggest that
GATA-3 plays an important role in the differentiation of
Th2 cells in conjunction with other transcription factors
such as nuclear factor of activated T cells (NF-AT)c/B, c-
Maf and STAT6 [9,22].
In both normal subjects and asthmatic patients, alveo-
lar macrophages and bronchial epithelial cells also
expressed STAT6 proteins. The predominant sites of
STAT6 expression in bronchial biopsies are epithelial
cells in all subjects. These results are in contrast to two
previous studies using immunohistochemistry in which
the authors were unable to find any STAT6 immunoreac-
tivity in nasal [15] and bronchial epithelial cells [16] but
Figure 2 Representative immunocytochemical staining for STAT6 in T-lymphocytes (A), CCR5- (B) and CCR5+ cells (C). STAT6 is localised
predominantly to the cytoplasm. However, in a small subset of T cells nuclear localisation of STAT6 can be detected. STAT6 is localised
predominantly to the nucleus of CCR5- but not CCR5+ cells.
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detected STAT6 localised to the nuclei of some infiltrat-
ing cells.
This discrepancy may depend upon differential expres-
sion of STAT6 in epithelial cells from upper and lower air-
ways since we found similar results with the two different
antibodies by Western blottings. However, we did not use
the same STAT6 antibodies (two mouse monoclonals
respectively from Transduction Laboratories and Santa
Cruz) as Ghaffer and colleagues [15] and Christodoulo-
poulos and colleagues [16] for immunostaining and their
sensitivity may differ. However, this is unlikely to account
for the different site of expression seen in bronchial air-
ways. Another study using immunohistochemistry with
the same antibody as used here has also shown that the
bronchial epithelium is the major site of STAT6 expres-
sion [23]. In addition, they also reported no difference
in the site of expression between asthmatic and normal
control subjects [17].
The presence of STAT6 immunoreactive cells with
nuclear localisation of STAT6 in the nasal mucosa of ato-
pic allergic rhinitis may be the result of a selective accu-
mulation of Th2 cells in this disease. This is in accordance
with the presence of a minority of T cells with nuclear
localisation of STAT6 demonstrated by immunostaining
and with the results of a previous study that showed no
activation of STAT6 in PBMCs from patients with acute
asthma [21].
Human bronchial epithelial cells and alveolar macro-
phages express IL-4R complex [24], respond to IL-4 and
IL-13 and produce cytokines such as GM-CSF and
eotaxin which contain STAT6-binding sites in the regula-
tory sequences of their genes [25-30]. In animal models
of allergic asthma, blockade of IL-13 markedly inhibits
allergen-induced airway hyperresponsiveness, mucus pro-
duction and eosinophilia [31]. Furthermore, IL-13 deliv-
ery to the airway causes all of these effects [31]. Mice
lacking STAT6 gene are protected from all pulmonary
effects of IL-13 [31]. Reconstitution of STAT6 only in
bronchial epithelial cells is sufficient for IL-13-induced
airway hyperresponsiveness and mucus production in the
absence of inflammation, fibrosis or other lung pathology
[31]. These results demonstrate the importance of direct
effects of IL-13 and STAT6 on epithelial cells in causing
two central features of bronchial asthma [31].
Interestingly, induction of inducible nitric oxide synthase
(iNOS) in both bronchial epithelial cells and alveolar
macrophages involves IL-4 and STAT6 [23,32]. These
data suggest that STAT6, which is key components of
Figure 4 Western blot analysis of STAT6 and phospho-STAT6
expression in bronchial mucosal biopsies of normal (N) and
asthmatic (As) subjects. Representative Western blot analyses of
experiments from 3 individual subjects in each group are shown (A).
Actin expression is used to control for protein loading. Graphical
representation of the data in (A) is shown in (B). (C) Failure to
detect phospho-STAT6 (pSTAT6) protein expression in bronchial
biopsies isolated from As and N subjects. pSTAT6 expression in
control IL-4 stimulated HeLa cells confirms the ability of the
antibody to detect pSTAT6. Each circle represents one subject.
Horizontal bars represent median values.
Figure 3 Representative Western blot analysis of STAT6 and
phospho-STAT6 protein expression in alveolar macrophages of
normal (N) and asthmatic (As) subjects. Representative Western
blot analyses of experiments from 3 individual subjects in each
group are shown (A). Actin expression is used to control for protein
loading. Graphical representation of the data in (A) is shown in (B).
(C) Failure to detect phospho-STAT6 (pSTAT6) protein expression in
alveolar macrophages isolated from As and N subjects. pSTAT6
expression in control IL-4 stimulated HeLa cells confirms the ability
of the antibody to detect pSTAT6. Each circle represents one
subject. Horizontal bars represent median values.
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signals via IL-4 and IL-13, may potentially play an impor-
tant role in modulating inflammatory gene expression in
alveolar macrophages and bronchial epithelial cells. How-
ever, our result demonstrated the same level of STAT6 in
T-lymphocytes, macrophages and bronchial epithelial cells
from all subjects with no difference between normal and
asthmatic subjects. There are some potential explanations
for these results. Firstly, the process of STAT-6 transloca-
tion from cytoplasm into nucleus is dependent of other
signals, such as Src kinase and phospholipase C activity
[33,34]. The existence of cytoplasmic STAT6 might
denote that other signals such as oxidative stress, which
may induce phospholipase C activity, is required for the
translocation of STAT6 into nucleus. Secondly, for IL-4/
IL-13-mediated pathway activation, there is also a STAT6-
independent process such as a acidic mammalian chitinase
[35]. In this paper, STAT6 activation was assessed using
immunoblotting. Additional data will be required to assess
STAT6 activation by quantative ELISA for identifying
transcription factor binding to DNA and chromatin
immunoprecipitation assay.
In the last decade many clinical studies have examined
the effect of blocking Th2 activity in human asthma.
Overall, these studies have proved disappointing in that
as a group mild-moderate asthmatics, similar to those
studied here, did not respond clinically to drugs target-
ing IL-4, IL-5 and IL-13 [36-38]. This raises the possibi-
lity that the underlying concept of asthma being a
Figure 5 Immunohistochemical staining for STAT6 protein in bronchial mucosal biopsies of normal (A) and asthmatic (B) subject, and
representative immunofluorescence staining for STAT6 in bronchial epithelial cells of an asthmatic subject (C).It indicates that STAT6 is
localised predominantly to the cytoplasm in bronchial cells of an asthmatic subject.
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Th2-driven hyper-eosinophilic disease which has been
developed in animal models is not reflected in human
disease except in small subsets of patients with selected
asthmatic phenotypes [36,37]. This further highlights
the need for more translational research into asthma
mechanisms in man if common drivers of disease in
human asthma are to be determined.
In summary, T cells from normal subjects and mild-
moderate steroid-naïve asthmatic patients in stable phase
asthmatics express similar levels of STAT6 protein within
each subcellular compartment. Alveolar macrophages and
bronchial epithelial cells also express STAT6 proteins with
equal expression in normal subjects and asthmatic
patients. STAT6 may be important in regulating the
expression of Th2-like cytokines in alveolar macrophages
and bronchial epithelial cells in addition to T cells in man.
Further studies with large number of participants are
needed to characterise fully the role of the STAT6 pro-
teins in the regulation of gene expression in these cell
types and their potential role in the pathogenesis of
asthma, because asthma has various phenotypes. A pre-
vious study suggested that treatment with topical gluco-
corticoids can reduce the number of CD3+/STAT6
immunoreactive cells in nasal mucosa [15]. However at
present the ability of glucocorticoids to target STAT6
action in the lower airways is unknown and may deter-
mine whether inhibition of STAT6 activity may be a new
therapeutic target for anti-asthma drugs.
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